Younger acute myelogenous leukemia patients respond favorably to anthracycline dose intensification
Induction therapy with higher daily doses of daunorubicin improved complete response and boosted overall survival in younger patients with acute myelogenous leukemia, according to results of the phase III ECOG E1900 trial. More »
Acute Lymphoblastic Leukemia Presenting as Soft Tissue Mass
For 3 months, a 9-year-old boy had swelling of the left upper arm. An MRI scan obtained at another facility 1 week after onset showed extensive edema of the soft tissue at the midhumeral level. Laboratory results, including complete blood cell (CBC) count and Lyme titer, were normal. More »
Bendamustine plus rituximab offers new standard of care for treatment of NHL and indolent lymphoma
There was good news at ASH 2009 on promising treatments for indolent lymphoma and aggressive non-Hodgkin's lymphoma. More »
Voreloxin Gets Orphan Drug Status for Acute Myeloid Leukemia
Advances in Genetics and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
Addition of rituximab improves OS in chronic lymphocytic leukemia
NEW ORLEANS—Genentech and Biogen announced at ASH 2009 that the three-year follow-up of the CLL8 trial demonstrated that rituximab (Rituxan) plus fludarabine and cyclophosphamide (FC) chemotherapy improved overall survival in patients with previously untreated chronic lymphocytic leukemia (CLL) vs FC therapy alone. More »
Current Management of Adult T-Cell Leukemia/Lymphoma
Adult T-cell leukemia/lymphoma (ATL) is defined as a histologically or cytologically proven peripheral T-cell malignancy associated with a retrovirus, human T-cell lymphotropic virus type I (HTLV-1).[1] Southwestern Japan is the district with the highest prevalence of HTLV-1 infection and the highest incidence of ATL in the world. A high prevalence of HTLV-1 infection is also found in the Caribbean islands, tropical Africa, South America, and northern Oceania. More »
Survivin(g) Adult T-cell Leukemia/Lymphoma
In this issue of ONCOLOGY, Tobinai reviews the management of human T-cell lymphotropic virus type 1 (HTLV-1)–associated adult T-cell leukemia/lymphoma (ATL). Although rare in the United States, an estimated 10 to 20 million people are infected with HTLV-1 worldwide and 2% to 5% will develop ATL.[1] More »
Adult T-cell Leukemia/ Lymphoma: Complexities in Diagnosis and Novel Treatment Strategies
In this issue of ONCOLOGY, Dr. Tobinai presents a thorough and thoughtful review of the current state of the art of HTLV-related adult T-cell leukemia/lymphoma (ATLL). As described, ATLL is most prevalent in Asia, where it has also been most studied, but is also seen in patients from other HTLV-endemic areas including the Caribbean, South America, and parts of Africa. ATLL is rare in North America and Europe, representing 1% to 2% of T-cell lymphomas compared to 25% in Asia.[1] More »
Oral JAK2 inhibitor deflates symptoms in myelofibrosis disease
NEW ORLEANS—A new treatment for patients who are severely debilitated by myelofibrosis offers hope of a return to normal daily life. Preliminary studies with an oral drug INCB018424 that targets the Janus-activated kinase (JAK) 2 gene appears to markedly reduce the swelling of the spleen and sometimes the liver, which can, in turn, can change patients’ quality of life. More »
Showing 1 - 10 of 130 results.
Page of 13
SearchMedica Search Results